GU Cancers 2024 | Nadofaragene firadenovec: an adenoviral vector-based gene therapy for bladder cancer

Siamak Daneshmand, MD, University of Southern California, Los Angeles, CA, gives an overview of nadofaragene firadenovec, an intravesical gene therapy indicated for patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer (NMIBC). Unlike chemotherapy, the gene therapy is not cytotoxic and consists of vector DNA in an adenoviral vector that encodes for interferon (IFN)-α2b. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.